• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Janssen Pharmaceuticals

European regulators offer positive opinion on Janssen’s schizophrenia treatment

September 17, 2021 By Sean Whooley

Updated Janssen logo

Johnson & Johnson’s Janssen Pharmaceutical Companies today announced a positive CHMP opinion on its Byannli schizophrenia treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued the positive opinion. The committee recommended using long-acting atypical antipsychotic Byannli (6-monthly paliperidone palmitate; PP6M) therapy for the maintenance treatment of schizophrenia. […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Janssen Pharmaceuticals, Johnson & Johnson

Pharma 50: Here’s how the world’s largest pharma companies are doing

May 12, 2021 By Chris Newmarker

Pharma 50 50 largest pharma companies pharmaceutical

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead. That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data […]

Filed Under: Featured, Pharmaceuticals Tagged With: AstraZeneca plc, Gilead Sciences, GlaxoSmithKline plc, Janssen Pharmaceuticals, Johnson & Johnson, Merck, Novartis, Pfizer Inc., Pharma 50, Roche, sanofi, Sinopharm

How PhysIQ is advancing digital therapeutics through its partnership with Janssen

May 12, 2021 By Sean Whooley

PhysIQ Janssen

Over the course of the last year and some change, the impact of digital health and the need for it has increased by an immeasurable amount. Virtual care became the norm after the COVID-19 pandemic hit, and, although a return to something resembling “normal” could be on the horizon, those at artificial intelligence-based technology developer PhysIQ see […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals, Technology Tagged With: Janssen Pharmaceuticals, Johnson & Johnson, PhysIQ

FDA approves oral multiple sclerosis treatment from J&J’s Janssen unit

March 19, 2021 By Sean Whooley

Updated Janssen logo

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announced today that it received FDA approval for its Ponvory treatment. Ponvory (ponesimod) is a once-daily, oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for treating adults with relapsing forms of multiple sclerosis (MS). It’s areas of treatment include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals Tagged With: Janssen Pharmaceuticals, Johnson & Johnson

FDA approves J&J’s Tremfya self-injection pen for psoriasis

January 30, 2019 By Nancy Crotti

FDA has approved Johnson & Johnson’s patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis. The self-injection approval may help Tremfya compete with AbbVie’s  (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients. Made by J&J subsidiary Janssen Pharmaceuticals (Horsham, Penn.), Tremfya is a biologic therapy that selectively […]

Filed Under: Auto-injectors, Drug-Device Combinations, Food & Drug Administration (FDA), Uncategorized Tagged With: AbbVie, FDA, Janssen Pharmaceuticals, johnsonandjohnson

J&J inks collab deal to develop MERS vaccine

September 27, 2018 By Fink Densford

Janssen

Healthcare giant Johnson & Johnson (NYSE:JNJ) today announced a new collaborative deal as it looks to develop a vaccine against Middle East Respiratory Syndrome Coronavirus. The collaborative deal is between J&J’s Janssen Vaccines & Prevention division, the Coalition for Epidemic Preparedness Innovations and The Jenner Institute at the University of Oxford, J&J said. Through the deal, Janssen […]

Filed Under: Featured, Pharmaceuticals, Research & Development Tagged With: Janssen Pharmaceuticals, johnsonandjohnson

J&J’s Janssen wins $45m BARDA contract for Ebola vaccine dev

October 2, 2017 By Fink Densford

Janssen

Johnson & Johnson (NYSE:JNJ) said today that its Janssen Pharmaceutical subsidiary Janssen Vaccines & Prevention B.V received a $44.7 million award and collaborative partnership from the US Biomedical Advanced Research and Development Authority to support its development of an investigational Ebola vaccine regimen. The deal comes with an option for BARDA to provide additional funding over 5 […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Research & Development Tagged With: Janssen Pharmaceuticals, johnsonandjohnson

J&J touts first-in-human data for HIV vaccine

July 24, 2017 By Sarah Faulkner

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) touted first-in-human clinical data today for its investigational HIV vaccine in development by its subsidiary, Janssen Pharmaceutical. The Phase I/IIa trial enrolled 393 healthy volunteers. According to the data, the vaccine was well-tolerated and triggered an HIV antibody response in 100% of participants. “Finding a preventive vaccine has proven to be one […]

Filed Under: Clinical Trials, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Janssen Pharmaceuticals, johnsonandjohnson

Medtech stories we missed this week: May 26, 2017

May 26, 2017 By Danielle Kirsh

missed medtech

From Merck’s new licensing agreement to surgical study data being touted, here are medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks exclusive licensing agreement for Alzheimer’s antibody Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. The […]

Filed Under: Clinical Trials, Diabetes, Diagnostics, Featured, Patient Monitoring, Pharmaceuticals, Regulatory/Compliance, Research & Development Tagged With: earlysense, Janssen Pharmaceuticals, Life Spine Inc., Masimo, medtech, Merck, Midmark, Procept BioRobotics, Shenzhen Lachesis Mhealth, Teijin Pharma, Thermi

Ichor Medical inks $85m drug-device deal with J&J

April 13, 2015 By Brad Perriello

Ichor Medical inks drug-device deal with J&J

Filed Under: Drug-Device Combinations Tagged With: Hepatitis, Ichor Medical Systems, Janssen Pharmaceuticals, johnsonandjohnson

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS